Focus on Animal Cells
Stem cell technology is widely considered to be the cutting edge of human medicine – Roslin Tech is applying its expertise to bringing similar state-of-the-art innovations to the animal and veterinary sectors.
Our stem cell platform (including induced pluripotent stem (iPS) cell lines) is focused on developing tools for the livestock, poultry and companion animal sectors, providing broad application and access to a variety of markets, including applications for therapy, drug and vaccine candidate screening, and cultured meat.
Stem cells are already exploited for a variety of treatments in humans and animals as they have the unique ability to be programmed into a range of tissues found in the body; our cell lines are already being used in exploratory research for canine diabetes.
Our cell lines can be used to support the multi-billion-dollar pharmaceutical screening sector for multiple species.
The cultured meat industry, growing rapidly after attracting $500 million of investment in the past three years, can use our cells as starting points to create bespoke products for the food sector.
Using outputs from the Roslin Institute, we have invested in a platform that exploits transgenic chickens that produce large quantities of proteins which we currently sell as research reagents. We are building this platform to produce new targets for the vaccine and therapeutics sectors.
Gene editing technology is embedded in several of our platforms and, in conjunction with partners, we are exploiting new gene editing technologies using cells derived from pigs, chickens, dogs, and crustacea.
For more information contact email@example.com